Role of topical phospholipids in the prophylaxis of silicone elastomer-associated infection in the abdominal cavity.
The present study evaluated the influence of phospholipids (phosphatidyl choline and phosphatidyl inositol) on the prevention of abdominal biomaterial-associated infection. Phospholipid-impregnated silicone elastomer (SE) fragments were either intraperitoneally implanted in rats or immersed in serum for 0, 4, and 14 days, and 3 x 10(9) cfu of 3H-labeled, live Escherichia coli were added in the peritoneal cavity or in vitro incubation medium. Three hours after incubation, the adherence of bacteria significantly decreased to phospholipid-impregnated SE fragments, which had been immersed/implanted for 0 and 4 days. However, the number of adhering bacteria did not differ between the impregnated and unimpregnated SE fragments after 14 days of immersion/implantation. A significantly lower number of adhering bacteria was noted on all unimpregnated SE fragments when phospholipid was supplemented in the peritoneal cavity or in vivo medium, compared with fragments with no supplement. The rate of bacterial DNA synthesis decreased significantly after incubation with phospholipid 2 h or more. Phospholipids did not further influence peritoneal morphology. Thus topical administration of phospholipids by impregnation to the surface of SE fragments or supplement in the incubation medium prevented bacterial adherence onto the SE fragments. This implies that the use of phospholipids might be a mode of preventing biomaterial-associated infections.
Guo
W
W
Department of Surgery, Lund University, Sweden.
Andersson
R
R
Bengmark
S
S
Ljungh
A
A
Willén
R
R
Liu
X
X
Carlsson
A
A
D000287:Administration, Topical; D000818:Animals; D001422:Bacterial Adhesion / Q000187:drug effects; D004269:DNA, Bacterial / Q000096:biosynthesis; D004926:Escherichia coli / Q000254:growth & development / Q000378:metabolism; D004927:Escherichia coli Infections / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D066298:In Vitro Techniques; D008297:Male; D010529:Peritoneal Cavity / Q000382:microbiology / Q000473:pathology; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000494:pharmacology*; D010716:Phosphatidylinositols / Q000008:administration & dosage / Q000494:pharmacology*; D016459:Prosthesis-Related Infections / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012826:Silicone Elastomers / Q000009:adverse effects*
D004269:DNA, Bacterial; D010713:Phosphatidylcholines; D010716:Phosphatidylinositols; D012826:Silicone Elastomers